CIN
MCID: CRV045
MIFTS: 39

Cervical Intraepithelial Neoplasia (CIN)

Categories: Rare diseases

Aliases & Classifications for Cervical Intraepithelial Neoplasia

MalaCards integrated aliases for Cervical Intraepithelial Neoplasia:

Name: Cervical Intraepithelial Neoplasia 52 54 71
Cin 47

Classifications:



External Ids:

UMLS 71 C0206708

Summaries for Cervical Intraepithelial Neoplasia

MalaCards based summary : Cervical Intraepithelial Neoplasia, also known as cin, is related to cervix uteri carcinoma in situ and suppressor of tumorigenicity 3. An important gene associated with Cervical Intraepithelial Neoplasia is CDKN2A (Cyclin Dependent Kinase Inhibitor 2A), and among its related pathways/superpathways are Keratinization and Pathways in cancer. The drugs Aluminum hydroxide and Epinephrine have been mentioned in the context of this disorder. Affiliated tissues include testes, cervix and t cells.

Wikipedia : 74 Cervical intraepithelial neoplasia (CIN), also known as cervical dysplasia, is the abnormal growth of... more...

Related Diseases for Cervical Intraepithelial Neoplasia

Diseases related to Cervical Intraepithelial Neoplasia via text searches within MalaCards or GeneCards Suite gene sharing:

(showing 252, show less)
# Related Disease Score Top Affiliating Genes
1 cervix uteri carcinoma in situ 33.8 KRT17 FHIT CDKN2A
2 suppressor of tumorigenicity 3 32.1 FHIT CDKN2A
3 in situ carcinoma 31.6 KRT8 KRT17 CDKN2A
4 chronic cervicitis 31.3 KRT17 CDKN2A
5 vulvar intraepithelial neoplasia 31.2 CDKN2A BIRC5
6 papilloma 31.0 KRT8 IVL CDKN2A
7 cervical squamous cell carcinoma 30.9 MKI67 KRT8 KRT17 CDKN2A
8 bowenoid papulosis 30.6 TERT CDKN2A
9 leukoplakia 30.4 MKI67 KRT8
10 keratinizing squamous cell carcinoma 30.4 KRT8 CDKN2A
11 squamous cell carcinoma 29.5 VEGFC NME1 MKI67 IVL FHIT CDKN2A
12 cervical cancer 29.0 VEGFC TERT TERC NME1 MTHFR KRT17
13 endometrial cancer 28.7 VEGFC TERT TERC NME1 MKI67 CDKN2A
14 renal cell carcinoma, nonpapillary 28.6 VEGFC NME1 MKI67 KRT8 FHIT BIRC5
15 basal cell carcinoma 28.5 TERT MKI67 KRT8 KRT17 IVL CDKN2A
16 breast cancer 26.6 VEGFC TERT NME1 MTHFR MKI67 KRT8
17 squamous cell papilloma 11.0
18 cervicitis 10.8
19 chlamydia 10.7
20 adenocarcinoma in situ 10.7
21 anogenital venereal wart 10.7
22 adenocarcinoma 10.6
23 immune deficiency disease 10.6
24 bacterial vaginosis 10.5
25 vaginal discharge 10.5
26 retinoblastoma 10.5
27 familial retinoblastoma 10.5
28 spitz nevus 10.4 MKI67 CDKN2A
29 ameloblastic carcinoma 10.4 MKI67 CDKN2A
30 vaginal cancer 10.4
31 cervix carcinoma 10.4
32 cecal benign neoplasm 10.4 TERT CDKN2A
33 cecum adenoma 10.4 TERT CDKN2A
34 pulmonary fibrosis, familial 10.4 TERT TERC
35 oral leukoplakia 10.4 MKI67 CDKN2A
36 inherited bone marrow failure syndromes 10.4 TERT TERC
37 malignant peritoneal mesothelioma 10.4 CDKN2A BIRC5
38 vaginitis 10.4
39 herpes simplex 10.4
40 adenosquamous carcinoma 10.3
41 placenta disease 10.3
42 47,xyy 10.3
43 cytokine deficiency 10.3
44 revesz syndrome 10.3 TERT TERC
45 adult malignant schwannoma 10.3 CDKN2A BIRC5
46 cryptogenic cirrhosis 10.3 MTHFR KRT8
47 hoyeraal hreidarsson syndrome 10.3 TERT TERC
48 dyskeratosis congenita autosomal dominant 10.3 TERT TERC
49 anus cancer 10.3
50 cervical adenocarcinoma 10.3
51 acral lentiginous melanoma 10.3 TERT CDKN2A
52 megaesophagus 10.3 FHIT CDKN2A
53 lymphoepithelioma-like thymic carcinoma 10.3 KRT8 CDKN2A
54 intrahepatic gall duct cancer 10.2 KRT8 KRT17
55 infiltrating angiolipoma 10.2 VEGFC CDKN2A
56 human immunodeficiency virus type 1 10.2
57 preterm premature rupture of the membranes 10.2
58 acute cervicitis 10.2
59 syphilis 10.2
60 lupus erythematosus 10.2
61 48,xyyy 10.2
62 dyskeratosis congenita, x-linked 10.2 TERT TERC
63 uterus carcinoma in situ 10.2 KRT17 FHIT CDKN2A
64 lung benign neoplasm 10.2 TERT FHIT CDKN2A
65 pleomorphic liposarcoma 10.1 KRT8 CDKN2A
66 keratocystic odontogenic tumor 10.1 MKI67 FHIT BIRC5
67 systemic lupus erythematosus 10.1
68 triiodothyronine receptor auxiliary protein 10.1
69 multinucleated neurons, anhydramnios, renal dysplasia, cerebellar hypoplasia, and hydranencephaly 10.1
70 alexithymia 10.1
71 ectopic pregnancy 10.1
72 pelvic inflammatory disease 10.1
73 vaginal disease 10.1
74 hepatitis a 10.1
75 amenorrhea 10.1
76 rectum cancer 10.1
77 vulvovaginitis 10.1
78 endometriosis 10.1
79 vaccinia 10.1
80 genital herpes 10.1
81 basaloid squamous cell carcinoma 10.1 KRT8 KRT17 CDKN2A
82 neutropenia 10.1
83 back pain 10.1
84 ductal carcinoma in situ 10.1 MKI67 KRT8 CDKN2A
85 pre-malignant neoplasm 10.1 KRT8 KRT17 CDKN2A
86 uterine carcinosarcoma 10.1 MKI67 KRT8 CDKN2A
87 anal canal carcinoma 10.1 NME1 CDKN2A
88 melanoma, cutaneous malignant 1 10.1 TERT TERC CDKN2A
89 barrett esophagus 10.1 MKI67 FHIT CDKN2A
90 tongue cancer 10.1 VEGFC TERT CDKN2A
91 dyskeratosis congenita, autosomal dominant 1 10.0 TERT TERC
92 acute kidney failure 10.0
93 pathologic nystagmus 10.0
94 idiopathic neutropenia 10.0
95 rapidly involuting congenital hemangioma 10.0
96 hypopharynx cancer 10.0 NME1 CDKN2A
97 bowen's disease 10.0 MKI67 IVL
98 alcohol dependence 10.0
99 autoimmune disease 10.0
100 colorectal cancer 10.0
101 hyperostosis cranialis interna 10.0
102 schistosoma mansoni infection, susceptibility/ 10.0
103 epidermodysplasia verruciformis 1 10.0
104 lymphoma, hodgkin, classic 10.0
105 proteasome-associated autoinflammatory syndrome 1 10.0
106 insulin-like growth factor i 10.0
107 adenomyosis 10.0
108 lymphoma, non-hodgkin, familial 10.0
109 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 10.0
110 leukemia, acute lymphoblastic 3 10.0
111 trichomonas vaginalis trichomoniasis 10.0
112 large cell neuroendocrine carcinoma 10.0
113 gastrointestinal carcinoma 10.0
114 endocervical adenocarcinoma 10.0
115 cervical polyp 10.0
116 bacterial infectious disease 10.0
117 endometriosis of ovary 10.0
118 oligohydramnios 10.0
119 vulva cancer 10.0
120 balanoposthitis 10.0
121 acute cystitis 10.0
122 urethritis 10.0
123 schistosomiasis 10.0
124 candidiasis 10.0
125 neuroendocrine carcinoma 10.0
126 viral hepatitis 10.0
127 trichomoniasis 10.0
128 cervix disease 10.0
129 ovarian brenner tumor 10.0
130 exocervical carcinoma 10.0
131 glomerulonephritis 10.0
132 papillary adenocarcinoma 10.0
133 gastrointestinal system cancer 10.0
134 teratoma 10.0
135 cervical carcinosarcoma 10.0
136 carcinosarcoma 10.0
137 pustulosis of palm and sole 10.0
138 ovarian cyst 10.0
139 infertility 10.0
140 rectum squamous cell carcinoma 10.0
141 ovarian squamous cell carcinoma 10.0
142 acquired immunodeficiency syndrome 10.0
143 b-cell lymphoma 10.0
144 cervical keratinizing squamous cell carcinoma 10.0
145 peritonitis 10.0
146 actinomycosis 10.0
147 polyhydramnios 10.0
148 oropharynx cancer 10.0
149 vasculitis 10.0
150 psoriasis 10.0
151 skin melanoma 10.0
152 viral infectious disease 10.0
153 placental abruption 10.0
154 cervical incompetence 10.0
155 trichorhinophalangeal syndrome 10.0
156 chromosomal triplication 10.0
157 erythroplakia 10.0
158 haemophilus influenzae 10.0
159 malignant cylindroma 10.0
160 inflammatory myopathy with abundant macrophages 10.0
161 carcinosarcoma of the cervix uteri 10.0
162 obsolete: squamous cell carcinoma of head and neck 10.0
163 argyria 10.0
164 polyploidy 10.0
165 lung giant cell carcinoma 10.0 NME1 CDKN2A
166 epidermolytic acanthoma 10.0 IVL CDKN2A
167 epidermoid cysts 9.9 KRT17 IVL
168 gastrointestinal stromal tumor 9.9 VEGFC MTHFR MKI67 CDKN2A
169 aniridia 1 9.9
170 burkitt lymphoma 9.9
171 optic nerve hypoplasia, bilateral 9.9
172 osteoporosis 9.9
173 ataxia-telangiectasia 9.9
174 fanconi anemia, complementation group d2 9.9
175 ataxia and polyneuropathy, adult-onset 9.9
176 aging 9.9
177 helicobacter pylori infection 9.9
178 asthma 9.9
179 yemenite deaf-blind hypopigmentation syndrome 9.9
180 homocysteinemia 9.9
181 bone mineral density quantitative trait locus 8 9.9
182 bone mineral density quantitative trait locus 15 9.9
183 aspergillosis 9.9
184 deficiency anemia 9.9
185 familial adenomatous polyposis 9.9
186 congenital stationary night blindness 9.9
187 colorectal adenocarcinoma 9.9
188 bone resorption disease 9.9
189 penile cancer 9.9
190 allergic hypersensitivity disease 9.9
191 telangiectasis 9.9
192 conjunctival squamous cell carcinoma 9.9
193 myoma 9.9
194 acute pancreatitis 9.9
195 ischemia 9.9
196 breast adenocarcinoma 9.9
197 plague 9.9
198 lynch syndrome 9.9
199 small intestine adenocarcinoma 9.9
200 conjunctival intraepithelial neoplasm 9.9
201 anal squamous cell carcinoma 9.9
202 kidney disease 9.9
203 conjunctivitis 9.9
204 adenoma 9.9
205 end stage renal failure 9.9
206 chronic kidney disease 9.9
207 night blindness 9.9
208 intermediate coronary syndrome 9.9
209 pemphigus 9.9
210 homocystinuria 9.9
211 acute myocardial infarction 9.9
212 allergic asthma 9.9
213 congenital nystagmus 9.9
214 hypereosinophilic syndrome 9.9
215 albinism 9.9
216 nephrogenic systemic fibrosis 9.9
217 splenomegaly 9.9
218 tetraploidy 9.9
219 encephalopathy 9.9
220 malignant tumor of penis 9.9
221 fibrillary astrocytoma 9.9 TERT CDKN2A
222 borst-jadassohn intraepidermal carcinoma 9.8 KRT17 IVL CDKN2A
223 epidermal appendage tumor 9.8 KRT8 IVL
224 keratosis, seborrheic 9.8 KRT17 IVL CDKN2A
225 keratosis 9.8 KRT17 IVL CDKN2A
226 laryngeal squamous cell carcinoma 9.8 TERT NME1 FHIT CDKN2A
227 mucoepidermoid carcinoma 9.8 MKI67 IVL CDKN2A
228 keratoacanthoma 9.8 MKI67 KRT17 IVL
229 skin squamous cell carcinoma 9.7 IVL CDKN2A BIRC5
230 cholangiocarcinoma 9.7 VEGFC TERT KRT8 FHIT
231 larynx cancer 9.7 VEGFC TERT NME1 CDKN2A
232 myelodysplastic syndrome 9.6 TERT TERC FHIT CDKN2A BIRC5
233 breast fibroadenoma 9.6 VEGFC NME1 MKI67 KRT8
234 breast ductal carcinoma 9.6 VEGFC NME1 MKI67 KRT8
235 pancreatic adenocarcinoma 9.5 VEGFC TERT CDKN2A BIRC5
236 nasopharyngeal carcinoma 9.5 VEGFC TERT NME1 CDKN2A
237 epidermolytic hyperkeratosis 9.5 SPRR1B KRT17 IVL
238 skin carcinoma 9.5 KRT8 IVL FHIT CDKN2A
239 gallbladder cancer 9.5 VEGFC TERT NME1 FHIT CDKN2A
240 melanoma, uveal 9.4 VEGFC TERT NME1 KRT8 CDKN2A
241 bladder urothelial carcinoma 9.4 VEGFC TERT MKI67 FHIT CDKN2A BIRC5
242 squamous cell carcinoma, head and neck 9.4 VEGFC NME1 FHIT CDKN2A BIRC5
243 esophageal cancer 9.3 VEGFC TERT MTHFR FHIT CDKN2A BIRC5
244 thyroid gland cancer 9.3 VEGFC TERT NME1 CDKN2A
245 transitional cell carcinoma 9.2 NME1 MKI67 KRT8 FHIT CDKN2A BIRC5
246 lung cancer susceptibility 3 9.2 VEGFC TERT KRT8 FHIT CDKN2A BIRC5
247 pancreatic cancer 9.0 VEGFC TERT TERC KRT8 FHIT CDKN2A
248 bladder cancer 8.8 VEGFC TERT TERC MKI67 KRT8 FHIT
249 gastric cancer 8.7 VEGFC TERT TERC NME1 MTHFR FHIT
250 gastric adenocarcinoma 8.6 VEGFC TERT NME1 KRT8 KRT17 FHIT
251 hepatocellular carcinoma 8.4 VEGFC TERT TERC NME1 MKI67 KRT8
252 prostate cancer 8.3 VEGFC TERT TERC NME1 MKI67 KRT8

Graphical network of the top 20 diseases related to Cervical Intraepithelial Neoplasia:



Diseases related to Cervical Intraepithelial Neoplasia

Symptoms & Phenotypes for Cervical Intraepithelial Neoplasia

Drugs & Therapeutics for Cervical Intraepithelial Neoplasia

Drugs for Cervical Intraepithelial Neoplasia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(showing 164, show less)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Aluminum hydroxide Approved, Investigational Phase 4 21645-51-2
2
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
3
Racepinephrine Approved Phase 4 329-65-7 838
4
Bupivacaine Approved, Investigational Phase 4 38396-39-3, 2180-92-9 2474
5 Monophosphoryl lipid A Phase 4
6 Central Nervous System Depressants Phase 4
7 Anesthetics, Local Phase 4
8 Epinephryl borate Phase 4
9 Neurotransmitter Agents Phase 4
10 Sympathomimetics Phase 4
11 Anti-Asthmatic Agents Phase 4
12 Vasoconstrictor Agents Phase 4
13 Adrenergic Agonists Phase 4
14 Adrenergic beta-Agonists Phase 4
15 Respiratory System Agents Phase 4
16 Autonomic Agents Phase 4
17 Mydriatics Phase 4
18 Bronchodilator Agents Phase 4
19 Adrenergic Agents Phase 4
20
leucovorin Approved Phase 3 58-05-9 6006 143
21
Lidocaine Approved, Vet_approved Phase 3 137-58-6 3676
22
Isotretinoin Approved Phase 3 4759-48-2 5538 5282379
23
Pancrelipase Approved, Investigational Phase 3 53608-75-6
24
Eugenol Approved Phase 3 97-53-0 3314
25
Aluminum sulfate Approved Phase 3 10043-01-3
26
Imiquimod Approved, Investigational Phase 3 99011-02-6 57469
27
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
28
Fenretinide Investigational Phase 3 65646-68-6
29
3,3'-diindolylmethane Investigational Phase 3 1968-05-4
30 Vitamin B Complex Phase 3
31 Vitamin B9 Phase 3
32 Folate Phase 3
33 Micronutrients Phase 3
34 Vitamins Phase 3
35 Trace Elements Phase 3
36 Hematinics Phase 3
37 Nutrients Phase 3
38 Retinamide Phase 3
39 Dermatologic Agents Phase 3
40 Antiviral Agents Phase 3
41 Antibodies Phase 3
42 Immunoglobulins Phase 3
43 Hemostatics Phase 3
44 Keratolytic Agents Phase 3
45 Pharmaceutical Solutions Phase 3
46 Anti-Arrhythmia Agents Phase 3
47 Sodium Channel Blockers Phase 3
48 Diuretics, Potassium Sparing Phase 3
49 Liver Extracts Phase 3
50 pancreatin Phase 3
51 Olive Phase 3
52 Immunologic Factors Phase 3
53 Anesthetics Phase 3
54 Adjuvants, Immunologic Phase 3
55 interferons Phase 3
56 Interferon Inducers Phase 3
57 Anti-Infective Agents Phase 3
58 Anti-Bacterial Agents Phase 3
59
Pemetrexed Approved, Investigational Phase 2 150399-23-8, 137281-23-3 446556 60843
60
Masoprocol Approved, Investigational Phase 1, Phase 2 27686-84-6, 500-38-9 71398
61
Zinc Approved, Investigational Phase 2 7440-66-6 32051
62
Cyclophosphamide Approved, Investigational Phase 2 50-18-0, 6055-19-2 2907
63
Omeprazole Approved, Investigational, Vet_approved Phase 2 73590-58-6 4594
64
Indomethacin Approved, Investigational Phase 2 53-86-1 3715
65
Nelfinavir Approved Phase 2 159989-64-7 64143
66
Fludarabine Approved Phase 1, Phase 2 21679-14-1, 75607-67-9 30751
67
Aldesleukin Approved Phase 1, Phase 2 110942-02-4, 85898-30-2
68 Raspberry Approved Phase 2
69
Artesunate Approved, Investigational Phase 2 88495-63-0 6917864 5464098
70
Aminolevulinic acid Approved Phase 2 106-60-5 137
71
Fluorouracil Approved Phase 1, Phase 2 51-21-8 3385
72
Histamine Approved, Investigational Phase 2 51-45-6 774
73
Glutamic acid Approved, Nutraceutical Phase 2 56-86-0 33032
74
Vitamin C Approved, Nutraceutical Phase 1, Phase 2 50-81-7 5785 54670067
75
Ornithine Approved, Nutraceutical Phase 2 70-26-8, 3184-13-2 6262
76
Epicatechin Investigational Phase 2 490-46-0, 35323-91-2 72276
77
Epigallocatechin gallate Investigational Phase 2 989-51-5 65064
78
Pyrazole Experimental Phase 2 288-13-1
79 Aluminum phosphate Phase 2
80 Folic Acid Antagonists Phase 2
81 Antioxidants Phase 1, Phase 2
82 Tea Phase 2
83 Coagulants Phase 2
84 benzenesulfonamide Phase 2
85 Carbonic Anhydrase Inhibitors Phase 2
86 Methyl 5-aminolevulinate Phase 1, Phase 2
87 Interferon-alpha Phase 1, Phase 2
88 Gastrointestinal Agents Phase 2
89 Tocolytic Agents Phase 2
90 Proton Pump Inhibitors Phase 2
91 Anti-Ulcer Agents Phase 2
92 Antacids Phase 2
93
protease inhibitors Phase 2
94 HIV Protease Inhibitors Phase 2
95 Anti-Retroviral Agents Phase 2
96 Anti-HIV Agents Phase 2
97 Interleukin-2 Phase 1, Phase 2
98 Antiparasitic Agents Phase 2
99 Antiprotozoal Agents Phase 2
100 Antimalarials Phase 2
101 Anthelmintics Phase 2
102 Artemisinins Phase 2
103 Artemisinine Phase 2
104 Photosensitizing Agents Phase 2
105 Immunosuppressive Agents Phase 1, Phase 2
106 Antimetabolites Phase 1, Phase 2
107 Antitubercular Agents Phase 2
108 Antibiotics, Antitubercular Phase 2
109
Histamine Phosphate Phase 2 51-74-1 65513
110 Histamine H1 Antagonists Phase 2
111 Histamine Antagonists Phase 2
112 Alkylating Agents Phase 1, Phase 2
113 Mitomycins Phase 1, Phase 2
114
Histidine Investigational, Nutraceutical Phase 2 71-00-1 6274
115
Curcumin Approved, Experimental, Investigational Phase 1 458-37-7 969516
116
Cidofovir Approved Phase 1 113852-37-2 60613
117
Zoledronic Acid Approved Phase 1 118072-93-8 68740
118
Motexafin lutetium Investigational Phase 1 246252-04-0
119 Poly I-C Phase 1
120 Cathartics Phase 1
121 Poly ICLC Phase 1
122 Laxatives Phase 1
123 Carboxymethylcellulose Sodium Phase 1
124 Senna Phase 1
125 Sennoside A&B Phase 1
126 Detox adjuvant Phase 1
127
Turmeric Approved, Experimental, Investigational Early Phase 1
128
Ethanol Approved 64-17-5 702
129
Cisplatin Approved 15663-27-1 84093 441203 2767
130
Topotecan Approved, Investigational 119413-54-6, 123948-87-8 60700
131
Nitrous oxide Approved, Vet_approved 10024-97-2 948
132
Iodine Approved, Investigational 7553-56-2 807
133
Methylcobalamin Approved, Investigational 13422-55-4
134
Hydroxocobalamin Approved 13422-51-0 11953898 15589840
135
Menthol Approved 2216-51-5 16666
136
Nicotine Approved 54-11-5 942 89594
137
Progesterone Approved, Vet_approved 57-83-0 5994
138
Proflavine Approved 92-62-6 7099
139
Tretinoin Approved, Investigational, Nutraceutical 302-79-4 5538 444795
140
Cyanocobalamin Approved, Nutraceutical 68-19-9 44176380
141
Vitamin A Approved, Nutraceutical, Vet_approved Early Phase 1 68-26-8, 11103-57-4, 22737-96-8 445354 9904001
142
Imidacloprid Vet_approved 105827-78-9 86418
143
Cobalamin Experimental 13408-78-1 6857388
144
Fenbendazole Vet_approved 43210-67-9 3334
145 Turmeric extract Early Phase 1
146 topoisomerase I inhibitors
147 Topoisomerase Inhibitors
148 Anesthetics, General
149 Anesthetics, Inhalation
150 Lugol's solution
151 cadexomer iodine
152 Vitamin B 12
153 Vitamin B12
154 Central Nervous System Stimulants
155 Cholinergic Agents
156 Nicotinic Agonists
157 Hormone Antagonists
158 Hormones
159 Progestins
160 Protective Agents Early Phase 1
161 retinol Early Phase 1
162 Retinol palmitate Early Phase 1
163 Anti-Infective Agents, Local
164 Vaccines

Interventional clinical trials:

(showing 301, show less)
# Name Status NCT ID Phase Drugs
1 A Randomized Controlled Trial Evaluating the Efficacy of Tachosil® for Prevention of Hemorrhage After Loop Electrosurgical Excisional Procedure (LEEP) in Patients With Cervical Intraepithelial Neoplasia or Cervical Cancer Unknown status NCT02629510 Phase 4 Tachosil
2 Can Mindfulness Meditation Limit the Progression and/or Increase the Remission of Cervical Dysplasia? Unknown status NCT00842738 Phase 4
3 HPV Vaccination Impact on Cervical Cancer Screening Program: FASTER-Tlalpan Study in Mexico Unknown status NCT03105856 Phase 4
4 Management of Cervical Intraepithelial Neoplasia Grade 2 Completed NCT00733109 Phase 4
5 A Phase IV Open-Label, Descriptive Study to Evaluate the Safety and Effectiveness on the Incidence of HPV 6, 11, 16 and 18 Related CIN 2/3 or Worse of the Quadrivalent HPV (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in 16- to 26-Year-Old Japanese Women Completed NCT01544478 Phase 4
6 Hemodynamic Stability of Bupivacaine With and Without Adrenaline for Paracervical Block for Cervical Conization During General Anesthesia: A Randomized Controlled Double Blinded Study Completed NCT02368054 Phase 4 Bupivacaine;Adrenaline
7 Comparison of Immune Response to the Human Papillomavirus Vaccine in Young Women With and Without Inflammatory Bowel Disease Completed NCT01034358 Phase 4
8 Immunogenicity and Safety of a Quadrivalent Human Papillomavirus (HPV) Vaccine in Patients With Systemic Lupus Erythematosus (SLE): a Controlled Study Completed NCT00911521 Phase 4 human papillomavirus vaccination (Gardasil)
9 Quadrivalent HPV Vaccination After Effective Treatment of Anal Intraepithelial Neoplasia in HIV+ Men Completed NCT02087384 Phase 4 Placebo
10 A Scientific Evaluation of One or Two Doses of Vaccine Against Human Papillomavirus: the ESCUDDO Study Recruiting NCT03180034 Phase 4
11 Safety and Protective Effect Study of GSK Biologicals' Human Papillomavirus (Types 16, 18) Vaccine, Adsorbed (GSK580299) in Healthy Female Subjects From the HPV-039 Study Active, not recruiting NCT03629886 Phase 4
12 Effectiveness of Cervical Screening in HPV Vaccinated Women - A Randomized Trial Enrolling by invitation NCT02149030 Phase 4
13 Randomized Controlled Trial of Vaginal Self Sampling for Human Papillomavirus to Increase Cervical Cancer Screening Participation Unknown status NCT01095198 Phase 2, Phase 3
14 The Study of Folate Receptor-Mediated Staining Solution (FRD™) In Cervical Unknown status NCT03366493 Phase 3
15 A Randomized Double-Blind Study of N-(4-hydroxyphenyl) Retinamide (4-HPR) Versus Placebo in Patients With Cervical Intraepithelial Neoplasia (CIN) Grade 2-3 Completed NCT00003075 Phase 3 Fenretinide
16 Randomized Trial of Immediate Treatment vs. Colposcopic Follow-up for Biopsy-Proven CIN 1 Completed NCT00156026 Phase 3
17 Topical Imiquimod in Treating Patients With Grade 2/3 Cervical Intraepithelial Neoplasia Completed NCT00941252 Phase 2, Phase 3 Topical imiquimod therapy
18 Long-term Extension Study of the Efficacy of the 580299 Vaccine in the Prevention of HPV-16 and/or HPV-18 Associated Cervical Intraepithelial Neoplasia (CIN) in Japanese Women Vaccinated in the Primary Vaccination Study NCT00316693 Completed NCT00929526 Phase 3
19 Persistence of Immune Response to GSK Biologicals' HPV Vaccine in Healthy Chinese Female Subjects From the HPV-058 Study Completed NCT03355820 Phase 3
20 A Double-Blind, Controlled, Randomized, Phase III Study of the Efficacy of an HPV16/18 VLP Vaccine in the Prevention of Advanced Cervical Intraepithelial Neoplasia (CIN2, CIN3, Adenocarcinoma In Situ [AIS] and Invasive Cervical Cancer) Associated With HPV 16 or HPV 18 Cervical Infection in Healthy Young Adult Women in Costa Rica. Completed NCT00128661 Phase 3
21 Diindolylmethane (DIM) Dietary Supplementation: A Nonsurgical Treatment for Cervical Intraepithelial Neoplasia (CIN) Completed NCT00212381 Phase 3 di indolylmethane (DIM)
22 An Investigation Into the Effects of Diidolylmethane (BioResponse DIM®) Supplementation in Women With Low-Grade Cervical Cytological Abnormalities [CRISP-1] Completed NCT00462813 Phase 3 oral microencapsulated diindolylmethane
23 Lidocaine Spray Compared With Submucosal Injection in Reducing Pain During Loop Electrosurgical Excision Procedure: a Randomized Controlled Trial Completed NCT01505920 Phase 3
24 A Phase III Randomized Trial of Topical Vaginal Fluorouracil (5-Fluorouracil, 5-FU) Maintenance Therapy Versus Observation After Standard Treatment for High-Grade Cervical Dysplasia in HIV-Infected Women Completed NCT00000758 Phase 3 Fluorouracil
25 Single Visit Cervical Cancer Prevention Program Completed NCT00237562 Phase 3
26 A Long-term, Open Follow-up of the Immunogenicity and Safety of GSK Biologicals' HPV Vaccine (580299) in Healthy Female Subjects Vaccinated in Study HPV-013 Completed NCT00316706 Phase 3
27 Large Loop Excision of Transformation Zone Cone Versus Straight Wire Excision of Transformation Zone : Histopathological Analysis of Excision Margins Completed NCT01929993 Phase 3
28 A Study to Evaluate the Efficacy of Quadrivalent HPV Vaccine in Reducing the Incidence of HPV 6-, 11-, 16-, and 18-Related CIN, AIS, and Cervical Cancer, and HPV 6-, 11-, 16-, and 18-Related External Genital Warts, Vulvar Intraepithelial Neoplasia Vaginal Intraepithelial Neoplasia, Vulvar Cancer, and Vaginal Cancer in 16- to 23-Year-Old Women Completed NCT00092521 Phase 3
29 Immunogenicity and Safety Study of a Bivalent Human Papillomavirus (Type 16, 18) Recombinant Vaccine (E.Coli) in Healthy Female Subjects Aged 9 to 17 Years Completed NCT02562508 Phase 3
30 Forced Versus Spray Coagulation in Women Undergoing LLETZ-conization for Cervical Dysplasia: a Randomized Trial Completed NCT02330471 Phase 3
31 A Study of Two Cone Biopsy Techniques For Women With Cervical Pre-Invasive Disease. LLETZ Cone and SWETZ. Completed NCT00995020 Phase 3
32 A Multi-Center, Double-Blind, Randomized, Placebo-Controlled Study of Amolimogene (ZYC101a) in the Treatment of High-Grade Cervical Intraepithelial Lesions (CIN 2/3) of the Uterine Cervix Completed NCT00264732 Phase 2, Phase 3 Amolimogene;Amolimogene
33 A Randomized, Placebo-Controlled, Double-Blind Study of Quadrivalent HPV (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine to Investigate the Safety, and Efficacy in Chinese 20 - to 45-Years-Old Women Completed NCT00834106 Phase 3
34 Phase 3 Randomized Controlled Trial of Non-inferiority of Topical Imiquimod vs. LEEP for Women With Carcinoma In-situ of the Cervix Completed NCT02130323 Phase 2, Phase 3 Imiquimod
35 A Randomized Phase III Trial of Oral Isotretinoin Versus Observation for Low-Grade Squamous Intraepithelial Lesions in HIV-Infected Women Completed NCT00001073 Phase 3 Isotretinoin
36 A Long-term, Open, Follow-up of the Immunogenicity and Safety of GlaxoSmithKline Biologicals' HPV-16/18 L1/AS04 Vaccine in Healthy Female Subjects Vaccinated Either Pre- or Post-menarche in the Primary Study Completed NCT00337818 Phase 3
37 Clinical Evaluation of the APTIMA® HPV Assay on the TIGRIS® DTS® System in Women With ASC-US Pap Test Results and in Women 30 Years of Age or Older With Negative Pap Test Results Using ThinPrep Pap Test Specimens Completed NCT00973362 Phase 3
38 Human Papillomavirus DNA Testing Using Self-collected Samples for Cervical Cancer Screening: an Alternative Strategy for Unscreened Women? Completed NCT01014026 Phase 3
39 Randomized Clinical Trial on Clinical Management of ASCUS and LSIL (ALTS) Completed NCT01131312 Phase 3
40 Safety and Immunogenicity of Human Papillomavirus (HPV) Vaccine in Solid Organ Transplant Recipients. Completed NCT00677677 Phase 3
41 Efficiency of AV2 Antiviral Drug in the Treatment of Human Papillomavirus-associated Precancerous Lesions of the Uterine Cervix: a Randomized Clinical Trial in Kinshasa, Democratic Republic of the Congo Completed NCT02346227 Phase 3 AV2;Placebo
42 Randomized Evaluation of VGX-3100 and Electroporation for the Treatment of Cervical HSIL Recruiting NCT03721978 Phase 3
43 A Phase 3 Randomized, Double-Blinded, Controlled With GARDASIL® Efficacy, Immunogenicity and Safety Study of V503 [a 9-Valent HPV Vaccine] in Chinese Women 20 to 45 Years of Age Recruiting NCT03998254 Phase 3 V503;Gardasil
44 A Randomized, Single Blinded Trial to Evaluate the Efficacy of Imiquimod in Women With Residual/Recurrent Cervical Intraepithelial Neoplasia (CIN) After Previous Treatment Recruiting NCT02669459 Phase 3 Imiquimod
45 A Prospective, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of VGX-3100 Delivered Intramuscularly Followed by Electroporation With CELLECTRA™-5PSP for the Treatment of HPV-16 and/or HPV-18 Related High Grade Squamous Intraepithelial Lesion (HSIL) of the Cervix Active, not recruiting NCT03185013 Phase 3
46 A Phase III Multicenter, Randomized, Double-Blind, Placebo(Hepatitis E Vaccine)Controlled Study to Evaluate the Efficacy, Immunogenicity and Safety of a Recombinant(E.Coli)Human Papillomavirus Bivalent Vaccine in Healthy Women Active, not recruiting NCT01735006 Phase 3
47 A Phase 3 Open-Label Clinical Trial to Study the Immunogenicity, Safety and Tolerability of Recombinant Human Papillomavirus Quadrivalent (Types 6, 11, 16, 18) Vaccine (V501) in Chinese Girls Aged 9-19 Years and Young Women Aged 20-26 Years Active, not recruiting NCT03493542 Phase 3
48 A Phase III Double Blinded, Randomized Controlled Study to Evaluate Efficacy of Protection Against HPV-16 and 18 Related Diseases, Immunogenicity and Safety of HPV-16/18 Vaccine in Healthy Females Aged 18-30 Years Active, not recruiting NCT02733068 Phase 3
49 A Randomised, Double-Blind, Placebo-Controlled, Phase III Study to Investigate the Efficacy of Presurgical 9-valent HPV Vaccination in Women Treated With LEEP for CIN 2+ and Initially Invasive Cervical Cancer. Not yet recruiting NCT03848039 Phase 3 Placebo
50 ITIC2 Trial - Topical Imiquimod Versus Conization to Treat Cervical Intraepithelial Neoplasia: Randomised Controlled, Non-inferiority Trial Terminated NCT01283763 Phase 3 Topical Imiquimod
51 Safety and Efficacy of Two Screen-and-Treat Approaches for the Prevention of Cervical Cancer Terminated NCT00233727 Phase 3
52 A Randomized Trial of Spectroscopy Versus Standard Care in Cervical Intraepithelial Neoplasia Terminated NCT00529464 Phase 3
53 TOPical Imiquimod Treatment of High-grade Cervical Intraepithelial Neoplasm: a Randomized Controlled Trial. Terminated NCT02329171 Phase 3 Imiquimod
54 A Randomized, Double-blind, Placebo-controlled, Multi-center, Phase 2 Clinical Trial to Evaluate the Efficacy and the Safety of GX-188E, a DNA-based Therapeutic Vaccine, Administered Intramuscularly by Electroporation(EP) in HPV Type 16 and/or 18 Positive Patients With Biopsy-proven Cervical Intraepithelial Neoplasia Grade 2(CIN2), Grade 2/3 (CIN2/3), Grade 3(CIN3) Unknown status NCT02596243 Phase 2
55 Phase II Randomized, Double-Blinded Trial Of SGN-00101 (HSP-E7) For Treatment Of CIN II/III Unknown status NCT00060099 Phase 2
56 Development and Application of a Diagnostic Imaging Aid for One-visit Management of Cervical Lesions in Low-resource Settings Unknown status NCT02406365 Phase 2
57 Phase 2a Double-Blind, Randomized, Parallel Group, Dose-Ranging Study to Assess the Safety and Efficacy of Three Doses of TVGV-1 Vaccine Compared to Its Adjuvant, GPI-0100, in Subjects With Histologically Confirmed HPV Induced Cervical HSIL Unknown status NCT02576561 Phase 2
58 Immunogenicity Study of a 2-dose Immunization Schedule of Recombinant Human Papillomavirus Virus-like Particle Vaccine (Type 16 and 18 L1 Proteins, Yeast) in Adolescent Females Aged 9 to 14 Years Unknown status NCT02740777 Phase 2
59 A Pilot Study of Photodynamic Therapy (PDT) Using Aminolaevulinic Acid (ALA) in Patients With HPV+ Low Grade Cervical Intraepithelial Neoplasia (LSIL;CIN1) Completed NCT02631863 Phase 2 Aminolaevulinic acid;Placebo
60 A Multi-center, Randomized, Double Blind, Placebo Control, Parallel Design, Phase 2a Trial to Evaluate the Efficacy and Safety of PGA (Poly-gamma Glutamic Acid) for the Fertile Women With Cervical Intraepithelial Neoplasia 1 (CIN1) Completed NCT01826045 Phase 2 Poly-gamma Glutamic Acid;Placebo
61 A Phase II Evaluation of Pemetrexed (Alimta) in the Treatment of Recurrent Carcinoma of the Cervix Completed NCT00190983 Phase 2 Pemetrexed
62 A Pilot Study of Aminolaevulinic Acid (ALA) Photodynamic Therapy (PDT) in Patients With Cervical Persistent High Risk HPV Infection or Cervical Intraepithelial Neoplasia Completed NCT02304770 Phase 2 Aminolaevulinic acid photodynamic therapy
63 A Phase 1/2a Trial to Evaluate the Efficacy and the Safety of BLS_ILB_E710c for the Fertile Women With Cervical Intraepithelial Neoplasia(CIN3) Completed NCT02195089 Phase 1, Phase 2 BLS_ILS_E710c 500mg;BLS_ILB_710c 1000mg;BLS_ILS_E710c 1500mg
64 An Exploratory Safety and Immunogenicity Study of Human Papillomavirus (HPV16+) Immunotherapy VB10.16 in Women With High Grade Cervical Intraepithelial Neoplasia (HSIL; CIN 2/3) Completed NCT02529930 Phase 1, Phase 2
65 A Randomized, Open-label, Multi-center, Phase 2 Clinical Trial to Determine the Optimal Dose and Evaluate the Safety of GX-188E, a DNA-based Therapeutic Vaccine, Administered Intramuscularly by Electroporation (EP) in HPV Type 16 and/or 18 Positive Patients With Cervical Intraepithelial Neoplasia 3 (CIN 3) Completed NCT02139267 Phase 2
66 Phase II Placebo Controlled Study of VGX-3100, (HPV16 E6/E7, HPV18 E6/E7 DNA Vaccine) Delivered IM Followed by Electroporation With CELLECTRA-5P for the Treatment of Biopsy-proven CIN 2/3 or CIN 3 With Documented HPV 16 or 18. Completed NCT01304524 Phase 2
67 A Randomized Double-Blind Study of Alpha-Difluromethylornithine (DFMO) Versus Placebo in Patients With Cervical Intraepithelial Neoplasia (CIN) Grade 2-3 Completed NCT00006079 Phase 2 Eflornithine
68 A Pilot Translational Study of Tetra-O-Methyl Nordihydroguaiaretic Acid (EM-1421) for the Treatment of Cervical Intraepithelial Neoplasia Induced by Human Papilloma Virus Completed NCT00154089 Phase 1, Phase 2 EM-1421
69 A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Trial of the Use of 4,4'-Dihydroxybenzophenone-2,4-Dinitrophenyl-hydrazone (A-007) Topical Gel in the Treatment of High-Grade Squamous Intraepithelial Lesions (HSIL) of the Cervix Completed NCT00285207 Phase 2 placebo;A007
70 A Randomized, Double-blind, Placebo-controlled, Parallel Group, Multicenter Study of the Safety and Response Rate of 3 Subcutaneously Administered Doses of 5 X 10^7 PFU RO5217790 in Patients With High Grade Cervical Intraepithelial Neoplasia Grade 2 or 3 Associated With High Risk HPV Infection Completed NCT01022346 Phase 2 Placebo;RO5217790
71 A Phase II Trial of Polyphenon E for Cervical Cancer Prevention Completed NCT00303823 Phase 2 placebo
72 A Phase I/II Clinical Trial of pNGVL4a-Sig/E7 (Detox)/HSP70 for the Treatment of Patients With HPV 16+ Cervical Intraepithelial Neoplasia 2/3 (CIN2/3) Completed NCT00121173 Phase 1, Phase 2
73 Phase II Topical Immunomodulatory Therapy With Imiquimod for the Chemoprevention of Recurrent and High-Grade Cervical Intraepithelial Neoplasia (CIN) Completed NCT00031759 Phase 2 imiquimod
74 Phase II Evaluation Of SGN-00101 (HSP-E7) Fusion Protein In Women With Cervical Intraepithelial Neoplasia 3, CIN 3 Completed NCT00054041 Phase 2
75 Randomized Clinical Trial Comparing Cold Knife Conization of the Cervix With and Without Lateral Hemostatic Sutures Completed NCT02184975 Phase 2
76 A Two-Stage Phase 2 Study Of Dose-Intense 4,4'-Dihydroxybenzophenone-2,4-Dinitrophenyl-Hydrazone (A-007) Topical Gel in the Treatment of High-Grade Squamous Intraepithelial Lesions (HSIL) of the Cervix Completed NCT00596258 Phase 2 A-007
77 Randomized Clinical Trial Comparing Two Techniques of Haemostasis After Cervical Conization With High Frequency Surgery Completed NCT03293628 Phase 2
78 A Randomized Phase II Dose-finding Study of Hexaminolevulinate (HAL) Photodynamic Therapy (PDT) in Patients With Low/Moderate-grade Cervical Intraepithelial Neoplasia (CIN1 or 2) Completed NCT01256424 Phase 2 HAL 5% with illumination;HAL 1% with illumination;HAL 0.2% with illumination;Placebo ointment without illumination
79 Vaginal Progesterone in the Treatment of Cervical Dysplasia Grade I and II: A Phase II Trial Completed NCT00247169 Phase 2 progesterone
80 SGN-00101 (HspE7) Immunotherapy Of CIN III Completed NCT00075569 Phase 2
81 A Randomized Double-Blind Phase II Trial of Celecoxib, A COX-2 Inhibitor, in the Treatment of Patients With Cervical Intraepithelial Neoplasia 2/3 or 3 (CIN 2/3 or 3) Completed NCT00081263 Phase 2 Celecoxib
82 Development and Application of a Multispectral Digital Colposcopy Algorithm for Detection of Cervical Intraepithelial Neoplasia and Neoplasia. Completed NCT01094132 Phase 2
83 A Randomized, Double-Blinded, Placebo-Controlled, Dose-Ranging Study of Recombinant Human Papillomavirus Virus 16/18 Bivalent Vaccine (E.Coli)in Healthy Female Subjects Aged 18 to 25 Years Completed NCT01356823 Phase 2
84 HPV Clearance by Folic Acid Supplementation (FACT for HPV) Completed NCT00703196 Phase 2
85 A Randomized, Double-blind, Multi-centre, Placebo Controlled Phase II Clinical Study to Evaluate the Efficacy, Tolerance and Safety of an Aqueous Gel Containing an Antiviral, Directly Applied on the Cervix Exhibiting High Grade Intraepithelial Lesion. Completed NCT01303328 Phase 2 C1
86 Methyl Aminolevulinate (MAL) and Hexaminolevulinate (HAL) Photodynamic Therapy (PDT)of Cervical Intraepithelial Lesions (SIL) - a Double-blind Dose-finding Study Completed NCT00369018 Phase 1, Phase 2 methyl aminolevulinate (MAL) and hexaminolevulinate (HAL)
87 A Phase II, Prospective, Open-label, Pilot Study of the Tolerability, Safety, and Efficacy of Argon Plasma Coagulation for the Treatment of Anal Intraepithelial Neoplasia Grade 2 or 3 in HIV-positive Men Having Sex With Men Completed NCT00428285 Phase 2
88 A Randomized Trial of Buffered vs Nonbuffered Lidocaine With Epinephrine for Cervical Loop Excision Completed NCT01405768 Phase 2 sodium bicarbonate buffered lidocaine;Non-buffered lidocaine
89 Therapeutic Vaccination Against Human Papillomavirus Type 16 for the Treatment of Anal Intraepithelial Neoplasia in HIV+ Men Completed NCT01923116 Phase 1, Phase 2 HPV-16 vaccine
90 A Phase 2b Trial to Evaluate the Efficacy and Safety of BLS-ILB-E710c in Patients With Cervical Intraepithelial Neoplasia 2/3 (CIN2/3) Recruiting NCT03274206 Phase 2 Placebo
91 Treatment of High-Grade Pre-Neoplastic Cervical Lesions (CIN 2/3) Using a Novel "Prime and Pull" Strategy Recruiting NCT02864147 Phase 2 9-valent HPV vaccine;Imiquimod
92 A Two-Cohort Randomized Phase 2 Trial of the IRX-2 Regimen in Women With Squamous Cervical Intraepithelial Neoplasia 3 (CIN 3) or Vulvar Intraepithelial Neoplasia 3 (VIN 3) Recruiting NCT03267680 Phase 2 Cyclophosphamide;Indomethacin;Omeprazole
93 A Phase II Clinical Trial of PepCan Randomized and Double-Blinded to Two Therapy Arms for Treating Cervical High-Grade Squamous Intraepithelial Lesions Recruiting NCT02481414 Phase 2
94 Evaluation of the Effect of the Combination of the Natural Products Glizigen® and Ocoxin®-Viusid® in the Treatment of High-grade Cervical Intraepithelial Lesions. Phase II Recruiting NCT03549273 Phase 2
95 A PHASE II SINGLE-ARM INTERVENTION TRIAL OF NELFINAVIR IN PATIENTS WITH GRADE 2/3 or 3 CERVICAL INTRAEPITHELIAL NEOPLASIA Recruiting NCT01925378 Phase 2 Nelfinavir
96 A Phase I/II Trial of T Cell Receptor Gene Therapy Targeting HPV-16 E7 With or Without PD-1 Blockade for HPV-Associated Cancers Recruiting NCT02858310 Phase 1, Phase 2 Aldesleukin;Fludarabine;Cyclophosphamide
97 A Randomized Study to Evaluate the Safety, Efficacy and Quality of Life of a New Device to Prevent Cervical Stenosis After LEEP in High Grade Cervical Dysplasia Active, not recruiting NCT02500966 Phase 1, Phase 2
98 Ensaio clínico Randomizado Avaliando a eficácia do Tratamento tópico Com Imiquimode em lesões Intraepiteliais Cervicais de Alto Grau Active, not recruiting NCT03233412 Phase 2 Imiquimod
99 A Phase 2 Trial to Evaluate the Efficacy and the Safety of Composite Gel Containing Black Raspberry Extract in Removing HPV From Patients With Cervical Intraepithelial Neoplasia(CIN) After Cervical Conization Not yet recruiting NCT03745846 Phase 2
100 A Phase II Double Blind, Placebo-controlled, Randomized Trial of Artesunate Vaginal Inserts for the Treatment of Patients With Cervical Intraepithelial Neoplasia (CIN2/3) Not yet recruiting NCT04098744 Phase 2 Artesunate vaginal insert;Placebo vaginal insert
101 A Randomized Phase II Study of Hexaminolevulinate (HAL) Photodynamic Therapy (PDT) in Patients With Low-grade Cervical Intraepithelial Neoplasia (CIN1) Terminated NCT00708942 Phase 2 Hexaminolevulinate (HAL);Placebo;Hexaminolevulinate (HAL);Placebo
102 A Randomized, Single Blind, Placebo Controlled Phase 2 Study to Assess the Safety of ADXS11-001 for the Treatment of Cervical Intraepithelial Neoplasia Grade 2/3 Terminated NCT01116245 Phase 2 Placebo Control
103 BrUOG 276: A Phase I/II Evaluation of ADXS11-001, Mitomycin,5-fluorouracil (5-FU) and IMRT for Anal Cancer Terminated NCT01671488 Phase 1, Phase 2 5FU;Mitomycin
104 Phase 2a Dose-Rising, Safety, Tolerability, and Efficacy Study of Topical SOR007 for Cervical Intraepithelial Neoplasia (CIN) Withdrawn NCT03143491 Phase 2 SOR007 (Uncoated Nanoparticulate Paclitaxel) Ointment
105 Phase II Trial of Nivolumab Based Immunotherapy for the Treatment of High-Grade Cervical Dysplasia Withdrawn NCT03808168 Phase 2 Nivolumab
106 S0212: Phase IIb Randomized Study of Celecoxib in Patients With High-Grade Squamous Intraepithelial Lesions of the Cervix Withdrawn NCT00072540 Phase 2 celecoxib
107 Novel Tumor Targeted Fluorescent TMTP1-ICG Mapping in Colposcopy-directed Biopsy Unknown status NCT03321461 Phase 1 TMTP1;ICG
108 A Multicenter, Nonrandomized, Open-Label Phase 1 Safety Study of HspE7 and Poly-ICLC Administered Concomitantly in Cervical Intraepithelial Neoplasia (CIN) Subjects Unknown status NCT00493545 Phase 1
109 Phase I, Open-Label Study of the Safety, Tolerability, and Immunogenicity of a Three Dose Regimen of Escalating Doses of PEK Fusion Protein Vaccine (PEK + GPI-0100) in Patients With LSIL or HSIL Unknown status NCT01880411 Phase 1
110 Safety Study of Transcription Activator-like Effector Nucleases T27 and T512 in HPV16-infected Subjects Unknown status NCT03226470 Phase 1
111 Safety Study of Zinc Finger Nucleases ZFN-602 and ZFN-758 in HPV-infected Subjects Unknown status NCT02800369 Phase 1
112 A Safety and Efficacy Study of Transcription Activator-like Effector Nucleases and Clustered Regularly Interspaced Short Palindromic Repeat/Cas9 in the Treatment of HPV-related Cervical Intraepithelial NeoplasiaⅠ Unknown status NCT03057912 Phase 1
113 A Single Center, Open-label, Dose-escalating, Phase Ι Study to Evaluate the Safety of GX-188E Administered by Electroporation (EP) in DNA-based Therapeutic Vaccine for Patients With Cervical Intraepithelial Neoplasia Grade 3 (CIN 3) Completed NCT01634503 Phase 1
114 A Phase I Study of Intravaginally Administered Artesunate In Women With High Grade Cervical Intraepithelial Neoplasia (CIN2/3) Completed NCT02354534 Phase 1 Artesunate Suppositories
115 A Randomised, Double-Blind, Placebo-Controlled, Multiple-Dose Study to Evaluate Safety, Tolerability and Pharmacokinetics of Topical ABI-1968 in Subjects With Cervical High Grade Squamous Intreaepithelial Lesions (cHSIL) Completed NCT03239223 Phase 1 ABI-1968
116 Phase I Trial on Safety and Pharmacokinetics of Intravaginal Curcumin in Normal Female Subjects Completed NCT01035580 Phase 1 Curcumin;curcumin
117 A Phase I Clinical Study to Evaluate the Tolerance and Safety of an Aqueous Gel Containing 2% (w/w) of Cidofovir, Directly Applied on the Cervix Exhibiting High Grade Squamous Intraepithelial Lesion(s) (CIN 2 and 3) Completed NCT00989443 Phase 1 Cidofovir gel
118 A Pilot Study of pnGVL4a-CRT/E7 (Detox) for the Treatment of Patients With HPV16+ Cervical Intraepithelial Neoplasia 2/3 (CIN2/3) Completed NCT00988559 Phase 1 imiquimod
119 A Single-Arm, Open-Label Pilot Study of the Safety and Immunogenicity of the Merck Quadrivalent Human Papillomavirus Vaccine Among HIV-Positive Women in India Completed NCT00667563 Phase 1
120 An Open-Label, Phase I, Escalating Dose Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of PDS0101 in Subjects With Cervical Intraepithelial Neoplasia (CIN) and High-risk Human Papillomavirus (HPV) Infection Completed NCT02065973 Phase 1
121 Phase I Open Label, Dose Escalation Study to Evaluate the Safety, Tolerability and Immunogenicity of Human Papillomavirus (HPV) DNA Plasmid (VGX-3100) + Electroporation (EP) in Adult Females Post Surgical or Ablative Treatment of Grade 2 or 3 Cervical Intraepithelial Neoplasia (CIN) Completed NCT00685412 Phase 1
122 The Development of a "Mother/Child, Screen, Treat and Vaccinate Program" in Manchay and Iquitos, Peru (PERCAPS) Completed NCT01338051 Phase 1
123 A Phase I Efficacy and Safety Study of HPV16-specific Therapeutic DNA-vaccinia Vaccination in Combination With Topical Imiquimod, in Patients With HPV16+ High Grade Cervical Dysplasia (CIN3) Recruiting NCT00788164 Phase 1 imiquimod
124 An Open-Label Multiple-Dose, Dose Escalation Study To Evaluate Safety, Tolerability and Pharmacokinetics of Topical ABI-1968 in Participants With Cervical High Grade Squamous Intraepithelial Lesions Recruiting NCT03697226 Phase 1 Topical ABI-1968
125 Clinical Study on the Regress of Cervical Intraepithelial Neoplastic(CIN) 1/CIN2 by Highly Effective DC Vaccines Targeting HPV E6/ E7 Protein Not yet recruiting NCT03870113 Phase 1
126 A Phase I Open Label, Dose Escalation Clinical Trial Assessing the Safety, Tolerability, and Feasibility of pNGVL4aCRTE6E7L2 HPV DNA Vaccine Administration Via Intramuscular TriGridTM Electroporation Delivery System to Patients With HPV16-Positive High-Grade Cervical Intraepithelial Neoplasia Not yet recruiting NCT04131413 Phase 1 pNGVL4aCRTE6E7L2
127 An Exploratory Clinical Trial of Zoledronic Acid in Women With CIN 2/3 or 3 Terminated NCT00278434 Phase 1 Zoledronate
128 Ex Vivo Gene Expression Profiling of Cervical Cancer Progression in Biopsies And Tissue Samples From Patients With Cervical Lesions Terminated NCT00629577 Phase 1
129 Phase I Study Photodynamic Therapy Using Lutrin (Lutetium Texaphyrin) in the Treatment of Patients With Cervical Intraepithelial Neoplasia Terminated NCT00005808 Phase 1 motexafin lutetium;photodynamic therapy
130 A Pilot Study: Measurement of Digital Colposcopy for Fluorescence Spectroscopy of the Normal Cervix for Screening, Using a Second Generation Device Withdrawn NCT00503919 Phase 1
131 Phase 1 of Serum IGF II and Cancer: Can IGF II Levels be Used to Monitor and Screen Patients Specifically for Cervical Cancer Unknown status NCT01371695
132 DNA Methylation Biomarkers for Cervical Cancer Screening Unknown status NCT02605941
133 A Randomized, Open-label Study to Evaluate the Safety and Efficacy of GX-188E, a DNA Therapeutic Vaccine Administered Intramuscularly by Electroporation, With GX-I7 Intravaginal Application or Imiquimod Topical Application in HPV16 and/or 18 Positive Patients With CIN3. Unknown status NCT03206138
134 A Prospective, Observational, Open-label, Multi-center, Follow-up Clinical Study to Determine Recurrence of Cervical Intraepithelial Neoplasia and Evaluate the Long-term Safety of GX-188E, a DNA-based Therapeutic Vaccine, Administered Intramuscularly by Electroporation (EP) in Subjects Who Were Diagnosed With HPV(Human Papillomavirus) 16 or 18 Positive Cervical Intraepithelial Neoplasia 3 (CIN 3) and Participated in Phase 2 Trial (GX-188E_CIN3_P2) Unknown status NCT02411019
135 A Single Center, Phase I Study to Follow-up on the Change of Immunogenicity and Lesion Condition in Subjects Who Have Completed the Phase I GX-188E Trial (Protocol no. GX-188E-SN) Unknown status NCT02100085
136 A Randomized Controlled Trial Comparing Concomitant HPV-cytology Testing With Conventional Cytology Testing for the Detection of High Grade Cervical Intraepithelial Neoplasia in Primary Cervical Cancer Screening in Hong Kong Unknown status NCT01058460
137 Randomized Implementation of Primary Human Papillomavirus (HPV) Testing in the Organized Screening for Cervical Cancer in Stockholm Unknown status NCT01511328
138 Morphometric Diagnosis of Atypical Glandular Lesions Using a Conventional Pap Smear From GOG-0171 Patients (Enrolled by GOG-Japan) With a Cytologic Diagnosis of Atypical Glandular Cells of Unspecified Significance (AGUS) Unknown status NCT00898144
139 Diagnostic and Prognostic Value of p16INK4a Expression in Low Grade Squamous Intraepithelial Lesions of the Cervix. Immunohistochemical Study on Biopsies (Retrospective and Prospective Analysis) and on Liquid Based (SurePath) Cervical Cytology (Prospective Analysis). Correlation With HPV Typing and Clinical Outcome. Unknown status NCT00343213
140 HPV Self-sampling as a Test of Cure After Treatment of Cervical Intra-epithelial Neoplasia Unknown status NCT02780960
141 Development and Application of a Multispectral Digital Colposcope and Probe Algorithm for Detection of Cervical Intraepithelial Neoplasia Unknown status NCT02406352
142 A Comparison of Immediate Treatment of CIN1 With Cryotherapy and Regular 12 Month Cytology Follow up in HIV Seropositive Women Unknown status NCT02250716
143 Effect of Curcumin in Treatment of Squamous Cervical Intraepithelial Neoplasias (CINs) Unknown status NCT02554344 Early Phase 1 Curcumin
144 The Effect of Physical Activity and Abstain From Smoking on the Regression of Precancerous Lesion. Unknown status NCT03093623
145 Study of Anal Cytologies in Patients With High Grade Cervical Intraepithelial Neoplasia (CIN II and III) Unknown status NCT03241680
146 Benign Hysterectomy; a Randomized Controlled Trial Comparing Robotic Hysterectomy With Vaginal Hysterectomy and Traditional Laparoscopic Hysterectomy Unknown status NCT01865929
147 Evaluation of Viral Load Determination and Other Biomarkers of High Risk HPV-Types as a Marker for Progression of Perianal HPV-infections in HIV-positive Men Who Have Sex With Men Unknown status NCT00365729
148 Pre-vaccination Distribution of Human Papillomavirus (HPV) Genotypes in Patients With High Grade Cervical Squamous Intraepithelial Lesion (HSIL) and Cervical Cancer From Croatia Unknown status NCT01385436
149 Activating Collaborative CIS Support Via Targeted Provider Mailing Unknown status NCT00873288
150 Prevaccination Distribution of Cervical Human Papillomavirus (HPV) Types and Their Associations With Invasive Cervical Cancer and Its Precursors in Yangtze River Delta Area, China Unknown status NCT01487681
151 Office Hysteroscopy Versus Stationary Coloposcopy for Diagnosis of Cervical Lesions in Women With Unhealthy Looking Cervix Unknown status NCT03150745
152 Validation of High Resolution Microendoscope in the Screening of Cervical Cancer Precursor Lesions in Brazil (UH3 - Brazil) Unknown status NCT03195218
153 The Study of Immunogenicity of Quadrivalent Vaccine Against Human Papilloma Virus (HPV) Types 6, 11, 16, and 18 (HPV-6/11/16/18) in CKD Patients Unknown status NCT01298869
154 HPV as Primary Screening Test in Cervical Cancer Prevention: From DNA to mRNA? A Randomised Controlled Trial Nested in a Double Testing Study With Long Term Follow up Unknown status NCT01837693
155 The Correlations Between HPV L1-Specific Immunologic Responses in Cervical Cancer and CIN Patients and Their Prognosis Unknown status NCT00728871
156 The Correlation Between the Haplotype of Human Leukocyte Antigen (HLA) and Human Papillomavirus Unknown status NCT00154479
157 The Development of Human Papillomavirus Type 16 E7-Specific Human Immunologic Assays in Non-HLA2 Type Human Being Unknown status NCT00155792
158 Comparison of the Human Papillomavirus (HPV) Type 16 E7-Specific Immune Response Between a Normal Population and Patients With Cervical Lesions Unknown status NCT00154583
159 Feasibility of a Randomised Controlled Trial of Laparoscopic Hysterectomy Versus Laparoscopic Sub-Total Hysterectomy Unknown status NCT01825915
160 Focal Ablation of High-grade Cervical Intraepithelial Neoplasia Completed NCT01709773
161 Measurement of Digital Colposcopy for Fluorescence Spectroscopy of Cervical Intraepithelial Neoplasia: A Pilot Study Completed NCT00602368
162 Factors Associated With Residual Disease In The Central Cone: A Disease Prediction Model Completed NCT03788850
163 Meta-analysis of Efficacy of Topotecan and Other Treatments for Recurrent Carcinoma of the Cervix Completed NCT01160185 paclitaxel;cisplatin;topotecan
164 HIV-Associated DNA Hypermethylation in Cervical Cancer Completed NCT00458562
165 Evaluation of the Use of Human Papillomavirus Persistence for Determination of the Treatment Efficacy Among Women With Cervical Intraepithelial Neoplasia, and for Prediction of Recurrence of Cervical Disease Completed NCT00931190
166 Quality of Life in Thai Women Diagnosed Cervical Cancer at King Chulalongkorn Memorial Hospital Completed NCT00741533
167 Effects of Music Listening During Loop Electrosurgical Excision Procedure on Anxiety, Pain, and Satisfaction: a Randomized Controlled Trial Completed NCT02398916
168 Presence of Positive Resection Margins, Hypooestrogenism and Specimen Volume May Influence Risk of Disease Recurrence in Patients With High-grade Cervical Intra-epithelial Neoplasia Undergoing Large Loop Excision of the Transformation Zone Completed NCT02540421
169 Investigational Study: Imaging the Uterine Cervix Using C30 Investigational Device Completed NCT00839475
170 Does Mozart Reduces Anxiety in Women With Cervical Dysplasia? A Randomized Controlled Trial. Completed NCT03005795
171 Study of the Diagnostic Efficacy of "Real Time" Niris 1300e Optical Coherence Tomography (OCT) Imaging System in the Management of Pre-invasive and Invasive Neoplasia of the Uterine Cervix (PUSHOCTII) Completed NCT01766284
172 Predictive Value of p16 and Ki-67 Immunohistochemical Staining and NK Cells in Expectant Management of Cervical Intraepithelial Neoplasia Grade 2 Completed NCT02522585
173 Measurement of Fluorescence EEM of Cervical Intraepithelial Neoplasia Completed NCT00632190
174 Endocervical Evaluation With the Curette Versus Cytobrush for the Diagnosis of Dysplasia of the Uterine Cervix Completed NCT01435590
175 Pathological Correlation of Colposcopically Directed Biopsies to Fluorescence EEM of the Normal Human Cervix Completed NCT00084903
176 Cervix Cytological Screening - Comparison of Tampon Self-Test and the Routine Smear. Completed NCT00377845 Early Phase 1
177 Does Live Video Colposcopy Reduces Anxiety in Women With Cervical Dysplasia? A Randomised Trial. Completed NCT02697175
178 Focal Loop Electrosurgical Excision Procedure for High-Grade Cervical Intraepithelial Neoplasia: an Alternative Treatment Approach Completed NCT02220192
179 Retinoids and Intermediate Biomarkers for CIN II and III: Pilot Trial Completed NCT00003598 tretinoin
180 Comparison of Human Papillomavirus Integrated DNA and Messenger RNA for Detection and Prediction in Progression of Cervical Neoplasia Completed NCT02198365
181 Cytology vs. at Home HPV Screening for Detection of CIN 2,3,CIS Completed NCT01550783
182 Impact of Cryotherapy Versus Loop Electrosurgical Excision Procedure (LEEP) on Recurrence of Cervical Intraepithelial Neoplasia and HIV-1 Cervical Shedding Among HIV-positive Women Completed NCT01298596
183 Genomics Approach to Id Novel Targets & Markers for Early Detection And Intervention In Cancer (Cervical) Completed NCT00601601
184 Expression of Oncogenic Human Papillomavirus E6/E7 Protein in Tampon Self-Tests Completed NCT00526370
185 Direct Colposcopic Vision and Large Loop Excision of the Transformation Zone in Women With Cervical Dysplasia: a Randomized Controlled Trial. Completed NCT02910388
186 A Cross-sectional, Hospital-based, Epidemiological Study on Human Papillomavirus Type Distribution in Adult Women Diagnosed With Invasive Cervical Cancer (ICC) and/or Cervical Intraepithelial Neoplasia (CIN) II and/or CIN III in Sri Lanka Completed NCT01221987
187 Impact of HPV Vaccine On The Prevalence Of Human Papillomavirus In Mouth And Vagina In Norway Completed NCT02934724
188 Impact of Anaesthesia Mode on Evaluation of LEEP Specimen Dimensions Completed NCT03737526
189 Immuno-persistence Study of A Bivalent Human Papillomavirus (Type 16, 18) Recombinant Vaccine (E.Coli) in Healthy Female Subjects Aged 9 to 17 Years Completed NCT03206255
190 IMproved PRactice Outcomes and Value Excellence in Colposcopy Completed NCT02185599
191 Indirect Comparison of the Efficacy Between Topotecan and Other Treatments for Recurrent Carcinoma of the Cervix Completed NCT01345279 cisplatin;topotecan;paclitaxel
192 Randomized Controlled Trial of Human Papillomavirus Testing in Primary Cervical Screening Completed NCT00479375
193 A Pilot Study to Evaluate Ultrasonic Surgical Aspiration as a Treatment Modality for Cervical Dysplasia Completed NCT00374114
194 CryoPen: An Innovative Treatment for Cervical Precancer in Low-Resource Settings Completed NCT02814448
195 A Pilot Study: Measurement of Digital Colposcopy for Fluorescence Spectroscopy of Cervical Intraepithelial Neoplasia Completed NCT00513123
196 Reflectance Confocal Imaging of Cervical Intraepithelial Neoplasia (CIN) Completed NCT00505726
197 A Feasibility Study of Molecular Imaging for Detection of Cervical Intraepithelial Neoplasia Completed NCT00511615
198 Double-Blinded Multicenter Clinical Study Assessing the Equivalence of the InPath Cervical Cell Collector to the Standard Endocervical Brush and Spatula in Patients Seeking Primary Pap Screening or Follow-up Screening Completed NCT00266084
199 Is a Hemostatic Procedure Required After Biopsy of the Cervix Uteri in Women Undergoing Colposcopy for Cervical Dysplasia? A Multicenter Randomized Non-inferiority Trial Completed NCT02486471
200 Imaging the Uterine Cervix - UltraSightHD™ Completed NCT01090635
201 Comparison of Pelvic Lymphadenectomy Versus Isolated Sentinel Lymph Node Biopsy Procedure for Early Stages of Cervical Cancers : a Randomized Multicenter Study With Evaluation of Medico-economic Impacts Completed NCT01639820
202 Clinical Evaluation of Polarized Light Assisted Colposcopy Completed NCT01349621
203 Safety and Validity Evaluation for Cervical Cancer Screening and Treatment Techniques Among HIV-infected Women Completed NCT02237326
204 Randomised Intervention Trial to Evaluate Single- and Double- Freeze Cryotherapy in the Prevention of Cervical Neoplasia Completed NCT01145781
205 Observational Study for Determine the Presence and Genotypes of HVP Infection in Cervical Intraepithelial Neoplasia Grade II-III (CIN II-III), and Stage I Cervical Epidermoid Carcinoma and Cervical Adenocarcinoma. Completed NCT00937547
206 A Multi-center Survey of HPV in Cervical Intraepithelial Neoplasia (CIN) With Longitudinal Follow-up of LSIL Cases Completed NCT00201370
207 Fischer Cone Biopsy Excisor Versus Loop Excision Procedure. A Randomized Trial of Two Operation Techniques in Women Undergoing Conization for Cervical Dysplasia Completed NCT02515162
208 Validation of Implementation of Cervical Dysplasia Treatment Modalities in HIV-Seropositive Women Completed NCT01723956
209 HPVPro Study: Comparison of HPV Detection in Clinician-collected Cervical Swabs and Self-sampled Cervicovaginal Swabs Completed NCT04133610
210 Phase 0 Study for the Development of Immunological Assays for the Evaluation of WT-1, Survivin and HPV16 E7 Tumor Antigens Specific Immune Responses in Cancer Patients Completed NCT02016833
211 Community Awareness, Resources and Education (CARE I): Project 3 Completed NCT02113514
212 Chinese Cancer Prevention Study(CHICAPS) Mass Population Based Cervical Cancer Screening Completed NCT01524003
213 Evaluation of Strategies for Optimal Clinical Management of Women With Atypical Squamous Cells of Undetermined Significance (ASC-US) Completed NCT02067468
214 Randomized Trial of In-Home Cervical Cancer Screening in Underscreened Women Completed NCT02005510
215 chemQbiosciences:Manual Liquid Based Cytology Completed NCT01837303
216 Effect of Fee on Attendance in Cervical Cancer Screening-results From ScreenFee a Swedish Population Based Randomised Trial Completed NCT02378324
217 Serum Levels of Folate And Vitamine B12 in Patients Infected With HPV and Diagnosed Atypical Squamous Cells of Undetermined Significance in Cervical Cytology Completed NCT03903952
218 Prevalence Rates of Sexually Transmitted Infections and Sexual Risk Behaviors Among African American Women Who Have Sex With Women Completed NCT01043081
219 Effect of Total Salpingectomy During Conservative Hysterectomy for Benign Disease on Ovarian Function: Non Inferiority Randomized Controlled Trial Completed NCT01628432
220 The HPV Self-test as a Test of Cure in the Follow-up of HPV-positive Women in Madagascar Completed NCT02811367
221 HPV Testing to Improve Cervical Cancer Screening in the Mississippi Delta (Mississippi Delta Project) Completed NCT00443313
222 Expression of the MN Protein in Atypical Glandular Cells of Undetermined Significance (Agus or Agcus) As a Potential Diagnostic Biomarker of Cervical Dysplasia/Neoplasia Completed NCT00003384
223 Immediate Smoking Cessation for Patients at Risk for Cervical Dysplasia, Cervical Cancer and Lower Genital Tract Dysplasia and Cancer - A Feasibility Study Comparing Nicotine Replacement Therapy With the Electronic Nicotine Delivery System. Completed NCT01989923
224 Long-term Immunogenicity of a Quadrivalent Human Papillomavirus (HPV) Vaccine in Patients With Systemic Lupus Erythematosus: a Case-control Study Completed NCT02477254
225 Prospective Case-control Study to Assess the Construct Validity of a Large Loop Excision of the Transformation Zone (LLETZ) Training Model Completed NCT02476500
226 Pilot Study of Immunogenicity and Tolerability to the Quadrivalent Human Papillomavirus Virus-like Particle (VLP) Vaccine (Gardasil) Among IBD Patients on Immunosuppressive Therapy Compared to Healthy Children and Youth Adult Females Completed NCT00727636
227 Optimal Timing for Performing Loop Electrosurgical Excision Procedure According to Different Menstrual Phase: Which is Best? Completed NCT03952975
228 Evaluation of the Satisfaction of Patients With Conization Under Local Anesthesia, Prospective Study Completed NCT03157752
229 A Comparison Study of Two Community Outreach-Based Approaches to Increase Participation of Women Living in the Mississippi Delta in Cervical Cancer Screening Completed NCT01058148
230 Genotypification and Predisposing Factors in Human Papilloma Virus Infection and Its Association With the Carbohydrate Antigen (CA-125) Tumoral Marker Completed NCT01924117
231 A Test of an Intervention to Improve Pap Testing Among Women With HIV Completed NCT01843478
232 HPV Infection and Cervical Lesions in HIV Infected Women in Thailand Completed NCT01792973
233 The Effect of Human Papilloma Virus Genotype on Women's Sexual Life Completed NCT03837028
234 Cervical And Self-Sample In Screening (CASSIS) Study: Diagnostic Performance of Molecular HPV Testing With the Eve Medical Self-collection System© for Detecting Cervical Intraepithelial Neoplasia Completed NCT02397252
235 Randomized Controlled Trial to Study Interventions to Increase Participation in Cervical Cancer Screening Program Completed NCT01029990 Early Phase 1
236 Prevalence and Persistence of Human Papillomavirus (HPV) and of Cervical Dysplasia in a Cohort of Women With Cystic Fibrosis Completed NCT03052556
237 Point‐of‐Care, Real‐Time Optical Imaging to Enable Screening for Cervical Cancer and Its Precursors in Low‐Resource Settings Completed NCT02494310
238 Low-Cost Molecular Cervical Cancer Screening Study Completed NCT01231945
239 A Randomized Trial To Compare An HPV Test-And-Treat Strategy To A Cytology-Based Strategy For Prevention Of CIN 2+ In HIV-Infected Women Completed NCT01315353
240 Study of HPV Self Testing Evaluation in the Province of Jujuy, Argentina Completed NCT02095561
241 Post Colposcopy Management of ASC-US and LSIL Pap Tests (PALS Trial): Pilot Study Completed NCT03466710
242 Can Text Reminders Improve Uptake of Cervical Screening? A RCT. Completed NCT02363088
243 Physical Cold Atmospheric Plasma for the Treatment of Cervical Intraepithelial Neoplasia Recruiting NCT03218436
244 HPV Integration Testing for Human Papillomavirus-Positive Women Recruiting NCT02576262
245 HPV(Human Papillomavirus) Integration Testing for Cervical Cancer Screening Recruiting NCT02576158
246 Detection of Biomarkers in First-void Urine Samples for Follow-up of Women Treated for High-grade Cervical Intraepithelial Neoplasia (CIN) Recruiting NCT03542513
247 Chronic Pelvic Pain With Vaginal Microbiota in Gestational Women Without HPV Infection Recruiting NCT03786588
248 The Effect of Cervical Morphological Changes on Pregnancy Outcome After Loop Electrosurgical Excision Procedure Recruiting NCT03242746
249 Large Loop Excision of the Transformatione Zone Under General Versus Local Anesthesia: a Randomized Trial. Recruiting NCT03494686
250 A Feasibility Trial of Alternating Intravaginal Application of 5-Fluorouracil and Imiquimod for Treatment of High-Grade Cervical Squamous Intraepithelial Lesions Recruiting NCT03196180 Early Phase 1 Imiquimod;Topical Fluorouracil
251 Correlation Between Colposcopist Findings and Digital Cervicography Employing Gynescope System Recruiting NCT03840187
252 Validation of Human Papillomavirus Assays and Collection Devices for HPV Testing on Self-samples and First-void Urine Samples (VALHUDES) Recruiting NCT03064087
253 Expectancy as Alternative to Treatment for Cervical Intraepithelial Neoplasia Grade 2 Among Women 25 - 30 Years of Age. A Multicenter Clinical Study Recruiting NCT03177863
254 Therapeutic Abstention and Surveillance of Intra-epithelial Histological Lesions of High Grade Cervical CIN2 (Cervical Intraepithelial Neoplasia Grade 2). SUIVICIN Recruiting NCT04057924
255 A Randomized Controlled Trial Comparing Cure Rates of Cervical Intraepithelial Neoplasia Grade 2 and Higher (CIN2+) Treated With CO2-based Cryotherapy, CropPen, and Thermoablation (UH3) Recruiting NCT03084081
256 Use of Condoms in Prevention of Progression of Cervical Intraepithelial Neoplasia: A Randomized Controlled Trial. Recruiting NCT02907333
257 Human Papillomavirus(HPV) Test of Urine and Self Collected Vaginal Samples for Cervical Cancer Screening Study Recruiting NCT03409471
258 Clinical Study on the Relationship Between Persistent Cervical HPV Infection With Clearance and Vaginal Microbial Community Recruiting NCT03895866
259 Effectiveness of HPV Vaccine Among Women Age Equal or More Than 20 Years Recruiting NCT03763565
260 The Overlooked Population at Risk for AIN: Women With High-grade Lower Genital Tract Dysplasia or Cervical Cancer. Recruiting NCT01953094
261 Prevalence of Anal Dysplasia and Anal Cancer in Women With Cervical, Vaginal and Vulvar Dysplasia and Cancer Recruiting NCT02140021
262 Epidemiologic and Molecular Features of Cervical Cancer in Nigeria - Project Itoju (Care) Recruiting NCT00804466
263 Performance, Safety, and Efficacy of a New Cryotherapy Device for Cervical Dysplasia Recruiting NCT04154644
264 Participation in Screening for Cervical Cancer: Interest of a Human Papillomavirus (HPV) Self-sampling Device Provided by the General Practitioner; a Cluster Randomized Clinical Trial Recruiting NCT02749110
265 A Comparative Evaluation to Evaluate the Correlation Between Cervical Cerclage or Vaginal Progesterone and Maternal Vaginal Microbiome Distribution During Pregnancy Recruiting NCT03253016
266 Compass - Randomized Controlled Trial of 5-yearly Cervical Screening With Primary HPV Testing Versus Cervical Screening With 2.5-yearly Liquid Based Cytology Testing, in HPV-Unvaccinated and HPV-Vaccinated Women in Australia Recruiting NCT02328872
267 Safety and Efficacy of Er:YAG and Nd:YAG Laser Therapy in Gynecology: A Retrospective Case Series. Active, not recruiting NCT04073082
268 A Prospective, Multi-centre Post Marketing Surveillance (PMS) Cohort Study to Monitor the Safety of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus (HPV)-16/18 L1 VLP AS04 Vaccine in Female Chinese Subjects Aged Between 9 and 45 Years, When Administered According to the Prescribing Information (PI) as Per Routine Practice. Active, not recruiting NCT03438006
269 Modifiable Factors Predicting Persistence of Oncogenic HPV and Cervical Dysplasia in HIV Infected Kenyan Women Active, not recruiting NCT04045652
270 Trial23 - Randomized Method Study on HPV-testing and Cytology Triage in Women Offered HPV-vaccination as Girls in Denmark Active, not recruiting NCT03049553
271 TOPical Imiquimod Treatment of High-grade Cervical Intraepithelial Neoplasia, a Multicenter, Open-label, Non-randomized, Controlled Study (TOPIC-3 Study) Active, not recruiting NCT02917746 Imiquimod
272 Evaluating Materials to Educate Patients About Cervical Dysplasia Active, not recruiting NCT00454766
273 Use of High-Resolution Microendoscopy (HRME) in Patients With Adenocarcinoma In-Situ (AIS) of the Cervix Active, not recruiting NCT02206048 Proflavine
274 Improving Cervical Cancer Prevention Among HIV-Infected Women Using Novel HPV Based Biomarker Assays Active, not recruiting NCT02247999
275 The SAFE Study: Satisfaction and Adherence to Follow-Up With Colposcopy Exams Active, not recruiting NCT03296566
276 Use of High-Resolution Microendoscopy (HRME) in Patients With Cervical Dysplasia Active, not recruiting NCT02420665 Early Phase 1 Proflavine;Acetic Acid
277 Performance, Safety, and Efficacy of a New Cyrotherapy Device for Cervical Dysplasia Active, not recruiting NCT02367625
278 Randomized Controlled Trial Comparing Routine Colposcopy to HPV Testing to Identify Persistent or Recurrent High Grade Cervical Cancer Precursors Active, not recruiting NCT01051895
279 A Study to Understand Cervical Cancer Early Endpoints and Determinants (SUCCEED) Active, not recruiting NCT00339989
280 Screening for Cervical Intraepithelial Neoplasia Using Self-collected Menstrual Blood Enrolling by invitation NCT03638427
281 Longitudinal Clinical Evaluation of the HPV Assay on the BD VIPER LT System With Cervical Specimens Enrolling by invitation NCT02267876
282 Coherence Imaging of the Cervical Epithelium With Scanning a/LCI Enrolling by invitation NCT03502798
283 Evaluation of Local Hyperthermia for the Treatment of Cervical Intraepithelial Neoplasias After 3 Months: a Multicenter, Single-blind, Randomized Controlled Trial Enrolling by invitation NCT03436251
284 HR-HPV Multi-site Opportunistic Screening in Liaoning, China Enrolling by invitation NCT03178136
285 A Long-term Follow-up Registry-based Cohort Study of HPV Vaccine Efficacy Against Cervical Pre-cancerous Lesions and Cervical Cancers in a Cohort of Females Previously Enrolled From Finland in Study HPV-008, as Compared to a Non-intervention Population -Based Reference Cohort of Females From Finland Enrolling by invitation NCT01393470
286 A Randomized Controlled, Open-label Trial Examining the Efficacy, Safety, and Tolerability of Ablative Therapies for High-grade Anal Dysplasia Versus Observation Alone in HIV-positive Men Who Have Sex With Men (MSM) Enrolling by invitation NCT02503111
287 THE EFFECTIVENESS OF MONOPOLAR HOOC VERSUS PLASMAKINETIC BİPOLAR SPATULA USAGE DURING COLPOTOMY PROCESS IN PATIENTS UNDERGOİNG TOTAL LAPAROSCOPIC HYSTERECTOMY Not yet recruiting NCT04191603
288 Deciphering Mechanisms Underlying Cancer Immunogenicity Not yet recruiting NCT03958240
289 Comparison of Cervical Intraepithelial Neoplasia 2/3 Treatment Outcomes With a Portable LMIC-adapted Thermal Ablation Device vs. Gas-based Cryotherapy Not yet recruiting NCT03429582
290 Screening for Anal Cancer in Women With High-grade Vulvar Dysplasia or Vulvar Cancer. Not yet recruiting NCT03061435
291 Cervical Cytology - Do SMS Reminders Increase Participation in the Cervical Screening Programme? Not yet recruiting NCT03975127
292 Intraoperative HPV Testing Evaluation: Multicenter Prospective Cohort Study Not yet recruiting NCT04190472
293 Co-registered Multimodal Optical Imaging for the Early Detection and Management of Cancers of the Vulva and Cervix Not yet recruiting NCT03285841
294 Acceptability and Efficacy of Self-sampling for Cervical Cancer Screening: A Pilot Study Not yet recruiting NCT03813576
295 Pilot Study of the Hand-held In Vivo Confocal Microscopy Probe for Detection of Cervical Intraepithelial Neoplasia Suspended NCT02574442
296 Evaluation of Initial High Risk Human Papillomavirus (HR-HPV) Viral Load as Predictive Marker for Cervical Intraepithelial Neoplasia Grade 1 (CIN1) Persistence Terminated NCT00682552
297 Pilot Study of a Digital Imaging Aid for Assessment of Cervical Dysplasia Terminated NCT00511758
298 Prognostic Value of Human Papillomavirus (HPV) Detection in Cervical Intra-epithelial Neoplasia (CIN) Recurrence After Conization: Prospective Study With Virological Follow-up on 24 Months (SUIVICOL) Terminated